Clinical Trial Update: ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) [Phase 2]

View source ↗

Summary

This document provides a Phase 2 clinical trial update for ARA-290, an erythropoietin analogue, in individuals with type 2 diabetes and related prediabetic cond…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Fasting Glucose
• Impaired Glucose Tolerance
• Prediabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• ARA-290 (ARA-290)

Snippet

Sponsor: Claes-Göran Östenson | Conditions: Diabetes Type 2, Impaired Glucose Tolerance | Phase 2 | Status: UNKNOWN